Clinical Behaviour of Prostatic Specific Antigen and Prostatic Acid Phosphatase: A Comparative Study

Robles, J. Morote; Morell, Á. Ruibal; Mateos, J A de Torres; Roselló, A Soler

doi:10.1177/172460088900400205

Cited by 10 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though the serum PAcP level is low in healthy individuals, its level is elevated in individuals with metastatic PCa and correlates with the stage of PCa [47–49]. Hence, elevated serum PAcP level was used as an indicator for the diagnosis of PCa until the availability of gold standard PSA.…”

Section: Biology Of Human Prostatic Acid Phosphatasementioning

confidence: 99%

Human Prostatic Acid Phosphatase: Structure, Function and Regulation

Muniyan

Chaturvedi

Dwyer

et al. 2013

IJMS

View full text Add to dashboard Cite

Human prostatic acid phosphatase (PAcP) is a 100 kDa glycoprotein composed of two subunits. Recent advances demonstrate that cellular PAcP (cPAcP) functions as a protein tyrosine phosphatase by dephosphorylating ErbB-2/Neu/HER-2 at the phosphotyrosine residues in prostate cancer (PCa) cells, which results in reduced tumorigenicity. Further, the interaction of cPAcP and ErbB-2 regulates androgen sensitivity of PCa cells. Knockdown of cPAcP expression allows androgen-sensitive PCa cells to develop the castration-resistant phenotype, where cells proliferate under an androgen-reduced condition. Thus, cPAcP has a significant influence on PCa cell growth. Interestingly, promoter analysis suggests that PAcP expression can be regulated by NF-κB, via a novel binding sequence in an androgen-independent manner. Further understanding of PAcP function and regulation of expression will have a significant impact on understanding PCa progression and therapy.

show abstract

Section: Biology Of Human Prostatic Acid Phosphatasementioning

confidence: 99%

Human Prostatic Acid Phosphatase: Structure, Function and Regulation

Muniyan

Chaturvedi

Dwyer

et al. 2013

IJMS

View full text Add to dashboard Cite

show abstract

“…The serum PSA levels were affected by age (5), total prostate volume (6), and prostatic pathology. Falsely elevated serum total PSA levels are found after some forms of prostatic manipulation (7), in the presence of urinary tract infection, prostatitis (8), and prostatic infarction (9), and after ejaculation (10). Many PSA parameters have been studied and explored to improve the performance of PSA.…”

Section: Introductionmentioning

confidence: 99%

Comparative Analysis of the Role of Prostate Specific Antigen Parameters in Clinical Practice

et al. 2000

View full text Add to dashboard Cite

Introduction: Serum prostate specific antigen at the cutoff levels of 4 ng/ml has low specificity for prostate cancer. We evaluated various PSA parameters (i.e., total PSA density [tPSAD], free PSA density [fPSAD], the ratio of free to total PSA [f/t ratio], and age-specific PSA) in terms of cancer diagnosis and reducing the number of negative results for prostatic biopsies. Materials and Methods: A series of 305 patients was studied. Serum tPSA and fPSA levels were measured. Prostate volume was measured with transrectal ultrasound, and sextant biopsies were performed. The f/t ratio, tPSAD, and fPSAD were calculated. Sensitivity and specificity were calculated for age-specific PSA. Receiver operating characteristic curve analysis was used to analyze the diagnostic performance of these PSA parameters. A subpopulation of patients with serum PSA levels between 4 and 10 ng/ml also was analyzed with a specific view to reducing negative results of biopsies. The Mann-Whitney U test was used to analyze the difference in these parameters between patients with benign and malignant histologies. Results: There was significant difference in these PSA parameters between patients with benign and malignant histologies (p < 0.05). tPSAD had the largest area under the curve for total population as well as for patients with tPSA levels between 4 and 10 ng/ml. Although the f/t ratio had a larger area under the curve than did tPSA assay in patients with PSA levels between 4 and 10 ng/ml, the difference was not statistically significant. Using a tPSAD of 0.12 ng/ml/ml as the cutoff level of negative results of prostate biopsies could be reduced by 37% in patients with PSA levels between 4 and 10 ng/ml. Although the f/t ratio could reduce negative results of biopsies by 33.8% at the cutoff value of 0.26, 15.6% of cancers would be missed. Age-specific PSA could reduce 31% of negative prostatic biopsies, but 28% of cancers would be missed. Using combined tPSAD and the f/t ratio did not improve reductions of negative biopsy results. Conclusion: tPSA density has the highest sensitivity and specificity in differentiating benign from malignant prostates. By using tPSA density, negative results of prostate biopsies can be reduced by 37%, while missing only a small number of cancers.

show abstract

“…This protein has been determined to be around 0.5 mg/g wet weight of prostate gland (Yam, 1974;Goldfarb et al, 1986) and 1.0 mg/mL in seminal fluid (Ronnberg et al, 1981). Serum levels of PAP are relatively low in healthy individuals, whereas elevated levels are observed in people with metastatic prostate cancer (Ahmann and Schifman, 1987;Robles et al, 1989;Simsek et al, 1992). Therefore, the elevated level of PAP together with total and non-PAP in prostate tissue of BPH rats is suggestive of aberration and abnormal biochemical reactions occurring in the tissue.…”

mentioning

confidence: 99%

Methyl Jasmonate Ameliorates Testosterone Propionate-induced Prostatic Hyperplasia in Castrated Wistar Rats

2017

View full text Add to dashboard Cite

Benign prostate hyperplasia (BPH) is a progressive disease that is related to age. Known therapeutic agents used in the treatment of BPH are associated with toxicity. Therefore, chemoprevention could be an effective approach. We investigated the ameliorative effects of methyl jasmonate (MeJA) in testosterone propionate (TP)-induced BPH in castrated rats. Castration was performed by removing both testes through the scrotum sack under ketamine anesthesia. Rats were assigned into seven groups of seven animals each: non-castrated control, castrated control, castrated rats that received TP, castrated rats that received TP and MeJA, castrated rats that received TP and finasteride, castrated rats that received MeJA, and castrated rats that received finasteride. Results indicate that BPH rats had significantly (p < 0.05) elevated prostate weight and relative weight of prostate relative to control. Also, BPH rats had significantly (p < 0.05) increased activities of prostatic acid and alkaline phosphatases, levels of zinc, and malondialdehyde. Further, levels of enzymic and non-enzymic antioxidative indices were significantly (p < 0.05) reduced in BPH. Histology of prostate revealed hyperplasia of transition lobe, increased expression of PSA, and Ki67 in BPH. Treatment with MeJA and finasteride attenuated the activities of the phosphatases and levels of antioxidants in BPH. Overall, MeJA ameliorates BPH via antioxidative mechanism. Copyright © 2017 John Wiley & Sons, Ltd.

show abstract

Clinical Behaviour of Prostatic Specific Antigen and Prostatic Acid Phosphatase: A Comparative Study

Cited by 10 publications

References 12 publications

Human Prostatic Acid Phosphatase: Structure, Function and Regulation

Human Prostatic Acid Phosphatase: Structure, Function and Regulation

Comparative Analysis of the Role of Prostate Specific Antigen Parameters in Clinical Practice

Methyl Jasmonate Ameliorates Testosterone Propionate-induced Prostatic Hyperplasia in Castrated Wistar Rats

Contact Info

Product

Resources

About